De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

InspireMD Toekomstige groei

Future criteriumcontroles 2/6

InspireMD zal naar verwachting zijn omzet verhogen met 59.5% per jaar.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	15.9%
Inkomstengroei	59.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	06 Aug 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:II2 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	30	N/A	N/A	N/A	1
12/31/2025	10	N/A	N/A	N/A	1
12/31/2024	7	N/A	N/A	N/A	1
6/30/2024	7	-26	-19	-18	N/A
3/31/2024	6	-23	-17	-17	N/A
12/31/2023	6	-20	-17	-16	N/A
9/30/2023	5	-19	-16	-15	N/A
6/30/2023	5	-19	-17	-16	N/A
3/31/2023	5	-18	-17	-16	N/A
12/31/2022	5	-18	-16	-16	N/A
9/30/2022	6	-18	-16	-15	N/A
6/30/2022	5	-17	-15	-14	N/A
3/31/2022	5	-16	-14	-14	N/A
12/31/2021	4	-15	-14	-13	N/A
9/30/2021	3	-15	-13	-13	N/A
6/30/2021	3	-13	-12	-11	N/A
3/31/2021	2	-12	-10	-10	N/A
12/31/2020	2	-11	-9	-9	N/A
9/30/2020	3	-9	-9	-8	N/A
6/30/2020	3	-9	-7	-7	N/A
3/31/2020	4	-9	-9	-9	N/A
12/31/2019	4	-10	-10	-10	N/A
9/30/2019	4	-10	-10	-10	N/A
6/30/2019	3	-10	-10	-10	N/A
3/31/2019	3	-8	-9	-9	N/A
12/31/2018	4	-8	-8	-8	N/A
9/30/2018	4	-11	-8	-8	N/A
6/30/2018	4	-11	-8	-8	N/A
3/31/2018	3	-12	N/A	-7	N/A
12/31/2017	3	-13	N/A	-8	N/A
9/30/2017	2	-10	N/A	-8	N/A
6/30/2017	2	-10	N/A	-9	N/A
3/31/2017	2	-9	N/A	-8	N/A
12/31/2016	2	-8	N/A	-7	N/A
9/30/2016	2	-9	N/A	-8	N/A
6/30/2016	2	-11	N/A	-7	N/A
3/31/2016	2	-13	N/A	-9	N/A
12/31/2015	2	-16	N/A	-12	N/A
9/30/2015	3	-18	N/A	-14	N/A
6/30/2015	2	-21	N/A	-18	N/A
3/31/2015	2	-24	N/A	-20	N/A
12/31/2014	3	-25	N/A	-19	N/A
9/30/2014	4	-26	N/A	-18	N/A
6/30/2014	5	-23	N/A	-15	N/A
3/31/2014	6	-30	N/A	-12	N/A
12/31/2013	6	-29	N/A	-11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van II2 boven de spaarquote ( 0.8% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van II2 naar verwachting sneller zal groeien dan de markt German

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van II2 naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van II2 ( 59.5% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.4% per jaar).

Hoge groei-inkomsten: De omzet van II2 ( 59.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van II2 naar verwachting over 3 jaar hoog zal zijn

InspireMD Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$0.82 loss per share (vs US$2.35 loss in FY 2022)

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Insider recently bought €116k worth of stock

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.59 loss in 2Q 2022)

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.53 loss in 3Q 2021)

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought €67k worth of stock

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.46 loss in 2Q 2021)

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

Insider recently bought €88k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

Insider recently bought €79k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Revenue misses expectations

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: €0.88

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: €0.64

New 90-day high: €0.50

Revenue beats expectations

Third quarter 2020 earnings released: US$0.064 loss per share

Inspiremd, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing

InspireMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

InspireMD, Inc. announced that it has received $0.1 million in funding

InspireMD Announces Gary S. Roubin, M.D., Ph.D., to Join Board of Directors

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives

InspireMD, Inc. to Report Q3, 2019 Results on Nov 12, 2019

New 90-day low: €0.28

InspireMD, Inc.(AMEX:NSPR) dropped from S&P TMI Index

New 90-day low - €0.32

New 90-day low - €0.35

InspireMD Regains Compliance with NYSE Listing Standards

InspireMD, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven